Safety profile of COVID-19 drugs in a real clinical setting
MN Chiu, M Bhardwaj, SP Sah - European journal of clinical pharmacology, 2022 - Springer
Purpose The coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) virus has affected millions all over the world and has …
syndrome coronavirus 2 (SARS-CoV-2) virus has affected millions all over the world and has …
Safety of short-term treatments with oral chloroquine and hydroxychloroquine in patients with and without COVID-19: a systematic review
S Marin, A Martin Val, M Bosch Peligero… - Pharmaceuticals, 2022 - mdpi.com
Chloroquine (CQ) and hydroxychloroquine (HCQ) have recently become the focus of global
attention as possible treatments for Coronavirus Disease 2019 (COVID-19). The current …
attention as possible treatments for Coronavirus Disease 2019 (COVID-19). The current …
Sinus bradycardia in a toddler with multisystem inflammatory syndrome in children (MIS-C) related to COVID-19
TC Hallberg, AR Bjorklund, TM Slusher… - … Case Reports CP, 2021 - casereports.bmj.com
This report documents a case of sinus bradycardia in a hospitalised 27-month-old girl with a
history of moderate persistent asthma, recent suspected viral respiratory infection and …
history of moderate persistent asthma, recent suspected viral respiratory infection and …